MEDICUS PHARMA LTD. (MDCX)

Import this data to Google Sheets with:

=jivedata("MDCX","financials")

Full statements spill as a table. For one cell: =jivedata("MDCX","Revenue") or =jivedata("MDCX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

MEDICUS PHARMA LTD.

MDCX • CIK 0001997296

(in thousands, except per share data)	FY 2024	FY 2025	TTM
General and Administrative Expense	$7,653.116	$17,920.391	$22,687.588
Research and Development Expense	$3,527.786	$7,721.436	$11,887.743
Operating Income (Loss)	$-11,180.902	$-34,359.302	$-43,292.806
Research and Development Expense (Excluding Acquired in Process Cost)	—	$8,717.475	$8,717.475
Operating Expenses	$11,180.902	$34,359.302	$43,292.806
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-11,155.516	$-35,444.361	$-44,892.607
Net Income (Loss) Available to Common Stockholders, Basic	$-11,155.516	$-47,281.659	$-51,221.562
Foreign Currency Transaction Gain (Loss), before Tax	—	$-10.73	$-214.979
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	—	$-47,292.389	$-56,690.42
Weighted Average Number of Shares Outstanding, Basic	9,619,184	17,283,824	50,997,464
Interest Income (Expense), Net	—	$-197.382	$-197.382
Gain (Loss) on Extinguishment of Debt	—	$-25	$-25
Other Nonoperating Income (Expense)	$25.386	$-1,085.059	$-1,599.801
Net Income (Loss) Attributable to Parent	$-11,155.516	$-47,281.513	$-56,662.869
Net Income (Loss) Attributable to Noncontrolling Interest	—	$-0.146	$-67.036
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	—	$-0.15	$0.563

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$4,164.323	$8,705.218	$15,174.128
Prepaid Expense, Current	$1,213.984	$1,086.121	$1,807.461
Operating Lease, Right-of-Use Asset	$268.571	$170.733	$117.184
Deferred Costs, Current	—	$99.305	$0
Assets	$5,646.878	$10,061.377	$27,116.185
Assets, Current	$5,378.307	$9,890.644	$16,981.589
Loans Payable, Noncurrent	—	$25.865	$17.114
Operating Lease, Liability, Noncurrent	$205.945	$60.139	$0
Liabilities	$2,512.174	$10,024.066	$28,841.149
Accounts Payable, Current	$1,284.612	$3,435.297	$6,734.31
Accrued Liabilities and Other Liabilities	$762.835	$995.29	$308.007
Operating Lease, Liability, Current	$116.323	$145.456	$137.33
Debt, Current	—	$5,245.543	$2,343.778
Liabilities, Current	$2,306.229	$9,938.062	$10,841.493
Common Stock, Value, Issued	$30,518.195	$57,076.175	$74,298.513
Additional Paid in Capital	$1,520.412	$6,879.575	$8,884.707
Accumulated Other Comprehensive Income (Loss), Net of Tax	—	$10.88	$61.095
Retained Earnings (Accumulated Deficit)	$-28,903.903	$-64,348.118	$-85,007.966
Stockholders' Equity Attributable to Parent	—	$-67.554	$-1,763.651
Stockholders' Equity Attributable to Noncontrolling Interest	—	$104.865	$38.687
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$3,134.704	$37.311	$-1,724.964
Common Stock, Shares Authorized	11,816,721	25,176,303	60,168,044
Prepaid Insurance	$583.561	$345.084	$109.405
Accrued Professional Fees, Current	$495.016	$352.864	$110.976
Employee-related Liabilities, Current	$140.989	$300.181	$195.082
Other Accrued Liabilities, Current	$126.83	$342.245	$1.949

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-11,155.516	$-35,444.361	$-44,892.607
Net Cash Provided by (Used in) Operating Activities	$-10,247.231	$-22,776.769	$-29,320.073
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	—	$-2.969	$81.54
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	—	$4,540.895	$15,521.994
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$4,164.323	$8,705.218	$11,088.412
Share-based Payment Arrangement, Noncash Expense	$713.119	$1,512.194	$3,287.601
Proceeds from Convertible Debt	$5,172.5	$0	$0
Paid-in-Kind Interest	$74.005	$429.061	$909.655
Proceeds from Issuance Initial Public Offering	$2,049.716	$0	$0
Proceeds from Issuance of Common Stock	$5,470	$9,790.015	$0
Proceeds from Issuance of Debt	—	$11,866.293	$29,366.293
Gain (Loss) on Extinguishment of Debt	—	$-25	$-25
Repayments of Debt	—	$7,391.107	$12,923.72
Research and Development Expense (Excluding Acquired in Process Cost)	—	$8,717.475	$8,717.475
Foreign Currency Transaction Gain (Loss), Realized	—	$-41.947	$-41.947
Proceeds from Warrant Exercises	—	$9,874.998	$8,897.6
Proceeds from Stock Options Exercised	—	$162.4	$162.4
Payments of Debt Issuance Costs	—	$136.726	$697.144
Payments of Stock Issuance Costs	—	$653.504	$653.504
Net Cash Provided by (Used in) Financing Activities	$12,692.216	$31,939.785	$49,379.679
Increase (Decrease) in Prepaid Expense	$1,040.265	$-352.825	$241.29
Increase (Decrease) in Deferred Charges	—	$99.305	$99.305
Net Cash Provided by (Used in) Investing Activities	—	$-4,619.152	$-4,619.152
Increase (Decrease) in Accounts Payable, Trade	—	$923.552	$3,666.683
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$358.018	$-438.802	$-2,184.348
IncreaseDecreaseInOperatingLeaseLiability	$-70.08	$-142.612	$-163.104
Increase (Decrease) in Accounts Payable, Related Parties	$-23.491	$-25.983	$40.573
Interest Paid, Excluding Capitalized Interest, Operating Activities	$40.563	$221.663	$552.289
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$356.805	$0	$0

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("MDCX","financials")

Full statements spill as a table. For one cell: =jivedata("MDCX","Revenue") or =jivedata("MDCX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.